Emcure Pharmaceuticals Intrinsic Value
Emcure Pharmaceuticals (EMCURE) median intrinsic value is ₹793.51 from 9 valuation models (range ₹489–₹1130), vs current price ₹1839.10 — -56.9% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit Emcure Pharmaceuticals share price chart.
EMCURE Valuation Methods Summary — DCF, Graham Number & P/E
Emcure Pharmaceuticals intrinsic value across 9 models vs current price ₹1839.10 — upside/downside and value range per method. Read Emcure Pharmaceuticals dividend policy for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1129.92 | ₹903.94 - ₹1355.90 | -38.6% | EPS: ₹51.36, Sector P/E: 22x |
| Book Value Method | asset | ₹488.63 | ₹439.77 - ₹537.49 | -73.4% | Book Value/Share: ₹244.32, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1045.89 | ₹941.30 - ₹1150.48 | -43.1% | Revenue/Share: ₹522.95, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1040.00 | ₹936.00 - ₹1144.00 | -43.5% | EBITDA: ₹1976.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹735.64 | ₹588.51 - ₹882.77 | -60.0% | CF Growth: 4.9%, Discount: 15% |
| PEG Ratio Method | growth | ₹551.73 | ₹496.56 - ₹606.90 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹793.51 | ₹714.16 - ₹872.86 | -56.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹919.55 | ₹827.60 - ₹1011.50 | -50.0% | ROE: 21.0%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹551.73 | ₹496.56 - ₹606.90 | -70.0% | EPS: ₹51.36, BVPS: ₹244.32 |
EMCURE Intrinsic Value vs Market Price — All Valuation Models
Emcure Pharmaceuticals fair value range ₹489–₹1130 vs current market price ₹1839.10 across 9 valuation models. Analyse Emcure Pharmaceuticals ownership pattern to track promoter, FII and institutional holdings.
EMCURE Intrinsic Value Analysis — Undervalued or Overvalued?
Emcure Pharmaceuticals median intrinsic value ₹793.51, current price ₹1839.10 — Trading Above Calculated Value by 56.9%, margin of safety -100.0%.
What is the intrinsic value of EMCURE?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Emcure Pharmaceuticals (EMCURE) is ₹793.51 (median value). With the current market price of ₹1839.10, this represents a -56.9% variance from our estimated fair value.
The valuation range spans from ₹488.63 to ₹1129.92, indicating ₹488.63 - ₹1129.92.
Is EMCURE undervalued or overvalued?
Based on our multi-method analysis, Emcure Pharmaceuticals (EMCURE) appears to be trading above calculated value by approximately 56.9%.
EMCURE Financial Health — Key Ratios vs Industry Benchmarks
Emcure Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 4.94 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 21.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.21x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
EMCURE Cash Flow Quality — Operating & Free Cash Flow
Emcure Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹852 Cr | ₹804 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1,097 Cr | ₹740 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹747 Cr | ₹513 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹768 Cr | ₹481 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹704 Cr | ₹576 Cr | Positive Free Cash Flow | 8/10 |